Is old age really a reason to withhold thrombolytic therapy?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 3, 2006, Pages 289-

  Schwark, C ^a   Schellinger, Peter D ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT;

AGE; AGED; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; DYING; EDITORIAL; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; NURSING HOME; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; HUMANS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; THROMBOLYTIC THERAPY; WITHHOLDING TREATMENT;

EID: 33644526278     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.080192     Document Type: Editorial

References (4)

1. The Third International Stroke Trial, http://www.dcn.ed.ac.uk/ist3 (accessed 26th October 2005).
2. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172(10):1307- 12.
3. The SITS study group. http://www.acutestroke. org/ (accessed 26 October 2005).
4. Kaste M. Thrombolysis: what more does it take? Stroke 2005;36(1):200-202.